In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com or follow us on LinkedIn.
Pieris and Boston Pharmaceuticals Immuno-Oncology Collaboration
Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin®-antibody bispecific fusion protein. Boston Pharmaceuticals is responsible for further development of the program and the program is currently in a phase 1 clinical study.
Pipeline Chart
Immuno-Oncology
Candidate
Targets
Partner
Discovery
Preclinical
Phase 1
Phase 2
Candidate
PRS-342/BOS-342
Partner
Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started